Fmc- Lexington Southwest is a medicare approved dialysis facility center in Lexington, Kentucky and it has 17 dialysis stations. It is located in Fayette county at 978 Chas Drive, Lexington, KY, 40515. You can reach out to the office of Fmc- Lexington Southwest at (859) 260-1706. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmc- Lexington Southwest has the following ownership type - Profit. It was first certified by medicare in February, 2017. The medicare id for this facility is 182633 and it accepts patients under medicare ESRD program.
| Name | Fmc- Lexington Southwest |
|---|---|
| Location | 978 Chas Drive, Lexington, Kentucky |
| No. of Dialysis Stations | 17 |
| Medicare ID | 182633 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 978 Chas Drive, Lexington, Kentucky, 40515 | |
| (859) 260-1706 | |
| Not Available |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago
| NPI Number | 1518327048 |
| Organization Name | Fresenius Kidney Care Fayette Southwest |
| Doing Business As | Bio-medical Applications Of Kentucky, Inc. |
| Address | 978 Chas Dr Lexington, Kentucky, 40515 |
| Phone Number | (859) 260-1706 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 7 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 21 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 103 |
| Percentage of adult patients getting regular hemodialysis at the center | 87 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmc- Lexington Southwest with elevated calcium levels.
| Patients with hypercalcemia | 21 |
| Hypercalcemia patient months | 103 |
| Patients with Serumphosphor | 27 |
| Patients with Serumphosphor less than 3.5 mg/dL | 15 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 23 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 23 |
| Patient months included in arterial venous fistula and catheter summaries | 91 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 48 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 13 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
African Americans who smoke cigarettes are more likely than those who don't smoke to develop peripheral artery disease, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Albumedix Ltd. (‘Albumedix'), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
› Verified 3 days ago